Tim Guilliams, Healx CEO
Rare disease biotech raises $47M Series C, plans for Phase 2 trial
Cambridge, UK-based Healx has pulled in $47 million in a Series C round and has nabbed IND clearance from the FDA to run its first …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
